Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Thera Begins China Phase IA/IIB Trial of OX40+ Inhibitor for Atopic Dermatitis

publication date: Feb 1, 2024

Guangzhou Bio-Thera has begun dosing patients in a China Phase IA/IIB clinical trial to test the efficacy and safety of BAT6026 in patients with moderate to severe atopic dermatitis. BAT6026 targets the OX40/OX40L interaction to prevent T cell activation, while also depleting activated OX40+ T cells through an ADCC effect. OX40 is highly expressed by activated CD4+ and CD8+ T cells, which are present in many inflammatory diseases including AD. Bio-Thera expects BAT6026 will be effective in many inflammatory diseases. It was well tolerated in a Phase 1 dose escalation clinical study. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital